【摘要】 目的:观察奥沙利铂联合希罗达方案治疗晚期胃癌的临床疗效及不良反应。方法:36例晚期胃癌患者,给予该方案化疗:奥沙利铂100mg/m² d₁;希罗达1000mg/m²每日两次口服,d_1-14;每21天为1周期,至少完成2个周期。评价客观疗效和不良反应。结果:全组36例均可评价疗效,其中完全缓解（CR）2例,部分缓解（PR）13例,稳定（SD）11例,进展（PD）10例,总有效率（CR+PR）41.7%。中位肿瘤进展时间（mTTP）8.9个月,中位生存时间（MST）为10.2个月。不良反应主要是骨髓抑制,胃肠道反应及外周神经毒性。结论:FOLFOX₄方案治疗晚期胃癌的近期疗效较好,不良反应可以耐受。更多还原

【Abstract】 Objective:To evaluate the efficacy and toxicity of oxaliplatin combined with Xeloda in the treatment of advanced gastric cancer.Methods:Thirty six patients with advanced gastric cancer were treated with chemotherapy: oxaliplatin 100 mg/m²,ivgtt,d₁;Xeloda 1000mg/m² Bid,d_1-14.21 days for one cycle.All patients received two cycles at least.Efficacy and toxicity were evaluated.Results:All the 36 patients were evaluated,2 patients achieved complete remission（CR =5.6%）,17 patients partial remission（PR = 36.1%）,13 patients stable disease（SD = 30.6%）,7 patients progressire disease（PD = 27.8%）.The total response rate was 41.7%.The median time to progression（mTTP） was 8.9 months.The median survival time（MST） was 10.2 months,major toxicity included leucopenia,nausea,vomiting and neurosensory abnormity.Conclusion:Regimen of oxaliplatin combined with Xeloda is effective and tolerable in advanced gastric cancer.更多还原